期刊文献+

乳腺癌患者癌组织与血清HER-2的表达及临床价值 被引量:1

Clinical value of serum level and tissue expression of HER-2 in patients with breast cancer
下载PDF
导出
摘要 目的:探讨乳腺癌患者血清HER-2与组织HER-2表达水平的相关性,以及血清HER-2的临床应用价值。方法:实验组选取临床诊断并经病检确诊的乳腺癌40例,乳腺良性肿瘤47例,对照组选取健康体检者44例,统一检测血清HER-2水平。结果:乳腺癌患者血清HER-2水平和阳性率(42.5%)高于乳腺良性肿瘤患者(17.02%)和健康体检者(15.91%);差异均有统计学意义(P<0.05)。血清HER-2在乳腺癌中具有较好的灵敏度(66.66%)和特异度(81.82%)。组织HER-2阳性和组织Ki-67阳性的乳腺癌患者血清HER-2的水平和阳性率高于组织HER-2阴性和组织Ki-67阴性的乳腺癌患者(P<0.05);组织分级越高的乳腺癌患者血清HER-2的阳性率越高(P<0.05)。结论:血清HER-2在乳腺癌患者中水平升高,具有较高的灵敏度和特异度,且与组织HER-2的表达具有相关性,对乳腺癌患者的诊断、预后有一定提示价值,有望成为乳腺癌患者癌组织HER-2检测的补充手段。 Objective :To investigate the correlation between serum level and tissue expression of IIER-2 in patients with breast cancer as well as clinical value of serum IIER-2 in diagnosis of breast cancer. Methods:Observational group consisted of 40 malignant and 47 benign cases of clinically and patho- logically confirmed hreast lesions,and another 44 patients undergoing health examination were enrolled in the control group. All suhjeets were subjected to determination of serum level of I IER-2. Results:The serum I IER-2 level and its positive rate(42.5%) were significantly higher in breast cancer patients than those of benign breast lesions(17.02%) and healthy participants(15.91%). The difference was statistically significant(P〈0.05). Serum IIER-2 level had better sensitivity( 66.66% ) and specificity( 81.82% ) in breast cancer. Patients with positive tissue IIER-2 mad Ki-67 had higher serum IIER-2 lev- el than those with negative expression of IIER-2 and Ki-67(P〈0.05). Positive rate of IIER-2 tended to be higher with increase of the histological grading in breast cancer patients(P〈0.05). Conclusion:Serum IIER-2 level is significantly elevated in breast cancer patients, and has higher sensitivity and spe- cificity. Also, serum level of IIER-2 is correlated with tissue IIER-2 expression and valuable in diagnosis and predictor for prognosis of patients with hreast cancer,which may be expected to be the eomplementaryindicator for I IER-2 detection in breast cancer patients.
作者 刘小岑 秦明明 刘夏 浦春 LIU Xiaocen;QIN Mingming;LIU Xia;PU Chun(Clinical Laboratory,The Firet Affiliated llospital of Wannan Medical College,Wuhu 241001,China)
出处 《皖南医学院学报》 CAS 2018年第5期437-439,共3页 Journal of Wannan Medical College
基金 安徽省高校自然科学研究重点项目(kj2016A722)
关键词 乳腺癌 HER-2 血清 组织 breast cancer IIER-2 serum tissue
  • 相关文献

参考文献7

二级参考文献57

  • 1PengYuan Bing-heXu Da-tongChu.CORRELATION BETWEEN SERUM HER-2 ONCOPROTEIN AND PATIENTS WITH BREAST CANCER[J].Chinese Medical Sciences Journal,2004,19(3):212-215. 被引量:8
  • 2刘彩云,吴健,杨蔚,孙素莲,寿成超.早期乳腺癌患者手术、化疗后血清HER-2/neu ECD水平变化[J].中国肿瘤临床,2006,33(13):728-730. 被引量:2
  • 3Carney WP, Neumann R, Lipton A, et al. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer [J]. Clin Chem, 2003 , 49(10) : 1579-1598.
  • 4Carney WP, Neumann R, Lipton A, et al. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer [ J ].Clin Breast Cancer, 2004, 5(2) : 105-116.
  • 5Esteva FJ, Cheli CD, Fritsche H, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumabbased therapies [ J]. Breast Cancer Res, 2005, 7 (4) : R436- R443.
  • 6Fehm T, Becker S, Duerr-Stoerzer S, et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status [ J ]. Breast Cancer Res, 2007, 9 (5) : R74.
  • 7Regitnig P, Schippinger W, Lindbauer M, et al. Change of HER- 2/neu status in a subset of distant metastases from breast carcinomas [J]. J Pathol, 2004, 203(4) : 918-926.
  • 8Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease [J]. Br J Cancer, 2005, 93(5) : 552-556.
  • 9Garoufali A, Kyriakou F, Kountourakis P, et al. Extracellular domain of HER2 : a useful marker for the initial workup and follow-up of HER2-positive breast cancer [J]. J BUON, 2008, 13 (3) : 409-413.
  • 10Fehm T, Jager W, Kraemer S, et al. Changes of serum HER2 status during clinical course of metastatic breast cancer patients [ J]. Anticancer Res, 2004 , 24(6) : 4205-4210.

共引文献57

同被引文献14

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部